Exhibit 99.1
CytoDyn to Hold Webcast and Live Q/A on October 26
VANCOUVER, Washington, October 21, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTCQB: CYDY) (CytoDyn or the Company), a
late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief
Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will host an investment community webcast
on Tuesday, October 26, 2021.
CytoDyn will present for 30 minutes, and 60 minutes will be dedicated to live questions and answers.
|
|
|
Date:
|
|
Tuesday, October 26, 2021
|
Time:
|
|
1:00 pm ET 2:30 pm ET
|
Access:
|
|
https://goto.webcasts.com/starthere.jsp?ei=1507874&tp_key=38dad67e60&sti=cydy
|
Interested participants are encouraged to login early prior to the start of the event. This is a livestream presentation, and
a link will also be posted on CytoDyns website within approximately 48 hours after the presentation. The webcast host provides corporate visibility services to CytoDyn for a fee.
Further, the Company urges investors to vote the blue proxy card in advance of the Companys upcoming 2021 Annual Meeting of Stockholders scheduled for
October 28, 2021. If you have any questions or require any assistance in voting your shares, please contact our proxy solicitor:
Morrow Sodali LLC
Stockholders Call Toll Free: (800) 662-5200
Banks, Brokers, Trustees and Other Nominees Call Collect: (203) 658-9400
Email: cydy@info.morrowsodali.com
About
Leronlimab
The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab
to treat Human Immunodeficiency Virus (HIV) and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast
cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that binds to CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including nonalcoholic steatohepatitis (NASH). Leronlimab has been
studied in 16 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with HIV standard care in patients with multi-drug resistance to current available classes of HIV drugs).